Living for Years Without a Heart Is Now Possible

A device called the Total Artificial Heart helps some of the sickest heart-failure patients regain function — outside of the hospital — while awaiting a transplant.

7:00 AM

Author | Kevin Joy

It sounds like a byproduct of science fiction: a synthetic, battery-powered device designed to replace the work of the body's most crucial organ.

But the equipment, known as the Total Artificial Heart, offers a lifeline for some of the most severe heart-failure cases.

"That's what the evolution of technology can do," says Jonathan Haft, M.D., a cardiac surgeon at the University of Michigan Health System. "You're actually removing the heart and replacing it."

Haft pointed to his patient Stan Larkin, pictured above, a 25-year-old with a rare form of cardiomyopathy who lived for 555 days — outside of the hospital — using a Total Artificial Heart before receiving a heart transplant at UMHS in May. "He's absolutely thriving now."

The internal mechanics, which replace both ventricles and four heart valves, are regulated by two tubes that connect to a portable, 13.5-pound external air pump called the Freedom driver. (Until the Freedom driver's approval by the Food and Drug Administration two years ago, most recipients had to rely on a hulking, 418-pound driver the size of a washing machine, which kept them hospitalized full time.)

Launched in 1969 and evolving since the 1980s, the devices aren't for everyone.

Only the left ventricle is affected in about 85 to 90 percent of patients with advanced end-stage heart failure — which qualifies them for the smaller and less-invasive pump known as a left ventricular assist device (LVAD).  

For those facing biventricular failure, however, a Total Artificial Heart is "the only real option for them," Haft says.

Compared with the LVAD, implementation of the Total Artificial Heart is far less common.

Between one and seven such surgeries for the latter occur at UMHS each year, says Haft, who explained the particulars in his own words.

A SynCardia Total Artificial Heart device.

7 things to know about Total Artificial Hearts

They require surgery: The operation is not too dissimilar to a heart transplant; somewhere in the neighborhood of four to five hours. It can be complicated or challenged by prior operations. If someone has been in the hospital for a long period of time, the recovery could take months.

They are large: It's noticeably bigger than a normal human heart. Patients have to undergo a CT scan to determine if there's enough room. This particular device has a certain size requirement in the chest cavity. For normal-sized people with chronic heart failure, usually it fits.

SEE ALSO: A Congenital Condition that Lead to 'Surprise' Heart Surgery

They allow mobility: The Freedom driver has a battery, so patients can be relatively untethered for a period of about two to three hours. Patients can use backup batteries if they have to leave the house for longer amounts of time. Of course, they can plug into an outlet whenever needed.

They can be unwieldy: The external controller is large and heavy. It's a burden for people to have to carry all the time. It's very, very noisy. Another limitation is the two large hoses that exit the body can be cumbersome and potentially painful.

They carry risks: The No. 1 challenge is infection … (via) a piercing of the skin (for the hoses) where germs can get in. With a huge amount of interface between blood and foreign surface, there are hazards of clots forming on the inside of the body. And if a patient is taking blood thinners, they can develop bleeding complications.

They are temporary: There are challenges with long-term support, so it's intended for transplant-eligible patients or those we intend to provide a transplant once they become eligible. There are no specific time limits for the device, and the durability and risk of complications over time remain unknown.  

They are evolving: The 70cc pump (the volume of blood that fills the device) has size limitations. You can't implant it into somebody who is very small or in people with normal-sized hearts. An investigational 50cc pump currently in clinical trials could increase eligibility for small people and for women.


More Articles About:

Heart Health Heart Transplant Surgery Emerging Technologies Cardiovascular: Treatment & Surgery
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

A man sits on a large red tractor. Behind him a bunch of corn is stacked in the back of the vehicle
Health Lab

Michigan man undergoes complex heart repair after last minute surgery cancelation

A complex operation at U-M Health enabled surgeons to remove scar tissue surrounding Scott Roach's heart and successfully repair his failing mitral valve.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Three people in a bar watch a television displaying a sports logo and a person smiling. Shelves with bottles and a counter with glasses are visible.
Health Lab

Jalen Hurts’ blood clot diagnosis: doctors answer common questions

After Jalen Hurts’ blood clot diagnosis, Michigan Medicine experts explain clot risks, treatment and returning safely to sports.
A pill bottle is open and pills are placed onto a hand
Health Lab

Could a diabetes medication be the next wonder drug?

Researchers identified how sotagliflozin may reduce heart attack and stroke risk, potentially offering benefits beyond diabetes care